Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

Benzinga · 2d ago
Barclays analyst Christopher Pasquale initiates coverage on TransMedics Group (NASDAQ:TMDX) with a Overweight rating and announces Price Target of $120.